At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 136 enrolled
Drug / intervention
LHA510 ophthalmic suspension +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Masked, Vehicle-Controlled Proof-Of-Concept Study for Topically Delivered LHA510 as a Maintenance Therapy in Patients With Wet Age-Related Macular Degeneration (AMD)
In Brief
A Phase 2 clinical trial evaluating LHA510 ophthalmic suspension, LHA510 vehicle, and 1 other intervention for Exudative Age-Related Macular Degeneration. Completed, enrolled 136 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the efficacy of 84 successive days of topically administered LHA510 compared to vehicle in reducing the number of patients requiring intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) therapy (Lucentis®) for recurrence of active choroidal neovascularization (CNV).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartMar 2015
Primary CompletionSep 2016
Study CompletionOct 2016
TodayJul 2026
First PostedFeb 4, 2015
Enrollment StartMar 3, 2015
Primary CompletionSep 15, 2016
Study CompletionOct 18, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.4 years ago
Interventions
LHA510 ophthalmic suspensiondrug
LHA510 vehicledrug
Inactive ingredients used as a placebo comparator
Ranibizumab ophthalmic solutiondrug
For intravitreal (IVT) injection